Ardent Health Partners, Inc.

Ardent Health reported second quarter 2026 results on 4 August, with net income and earnings per share lower than a year earlier and full-year earnings guidance reduced. The company also updated on its ongoing share buyback program, which has now retired more than 1.2% of outstanding shares. Ardent Health shares have returned 33.68% year to date, though the one-year total shareholder return is slightly negative at 2.86% lower. The stock last closed at $11.55, below the average analyst price target of $12.50, with the most bullish target at $14.00 and the most bearish at $10.00. A Simply Wall St narrative fair value estimate of $12.50 suggests the stock is modestly undervalued, while a discounted cash flow model points to a fair value of $2.16, indicating overvaluation.